Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

Conclusion T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer. PMID: 28056202 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28056202?dopt=Abstract

Source: Clinical Breast Cancer - January 7, 2017 Category: Cancer & Oncology Authors: Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P Tags: J Clin Oncol Source Type: research